Jones Financial Companies Lllp Acquires 75 Shares of Penumbra, Inc. (NYSE:PEN)

Jones Financial Companies Lllp increased its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 25.0% during the fourth quarter, Holdings Channel reports. The fund owned 375 shares of the company’s stock after purchasing an additional 75 shares during the period. Jones Financial Companies Lllp’s holdings in Penumbra were worth $89,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of PEN. True Wealth Design LLC bought a new position in Penumbra in the 3rd quarter valued at $26,000. UMB Bank n.a. boosted its position in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares during the last quarter. Mather Group LLC. boosted its position in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after buying an additional 208 shares during the last quarter. Advisors Asset Management Inc. boosted its position in Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after buying an additional 43 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Penumbra by 160.8% in the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock valued at $106,000 after buying an additional 275 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PEN. Oppenheimer began coverage on Penumbra in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective on the stock. StockNews.com downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Truist Financial increased their price target on Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. increased their price target on Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Finally, Morgan Stanley increased their price target on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Penumbra currently has an average rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Stock Performance

Shares of Penumbra stock opened at $273.51 on Monday. The company has a market capitalization of $10.53 billion, a PE ratio of 804.45, a PEG ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $269.89 and its 200 day simple moving average is $237.89.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. On average, research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Buying and Selling at Penumbra

In other Penumbra news, CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $286.00, for a total value of $572,000.00. Following the sale, the chief financial officer now owns 15,243 shares of the company’s stock, valued at $4,359,498. This trade represents a 11.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $242.96, for a total value of $3,644,400.00. Following the completion of the sale, the chief executive officer now directly owns 837,582 shares in the company, valued at $203,498,922.72. This represents a 1.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,918 shares of company stock valued at $22,054,293 in the last 90 days. 5.00% of the stock is currently owned by company insiders.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.